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Abstract 
 
Clinical Implication of Hypervascular Enhancing Foci on Arterial Phase 
Images of Multiphase Dynamic CT in the Cirrhotic Liver 
 
Sung Ho Hwang 
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Choon Sik Yoon) 
 
 
Objective: Our purpose was to determine the significance of small 
hypervascular enhancing lesions exclusively on arterial phase images of 
dynamic CT in the cirrhotic liver. 
Methods: One-hundred-sixty-nine enhancing lesions (> 5 mm and < 30 mm) on 
the arterial phase images of dynamic CT in 67 patients with cirrhotic liver, not 
distinguished from background hepatic parenchyma on equilibrium phase 
images without hypoattenuation density on portal phase images, were subjected 
to a retrospective assessment in terms of the lesion-growth in addition to the 
location, size and contour of the lesions depending on the final diagnoses of the 
individual lesions.  
Results: Twenty-eight (17%) of the 169 enhancing lesions were hepatocellular 
carcinomas (HCCs). All of the 43 wedge-shaped, subcapsular lesions were 
benign, and 126 nodular or irregular lesions were subcapsularly (benign, n = 59; 
 2 
HCC, n = 11) or centrally (benign, n = 39; HCC, n = 17) located. Significant 
differences were found between HCCs and benign lesions in terms of their 
shape (p = 0.002) and location (p = 0.041), and the positive and negative 
predictive values (PPV, NPV) of centrally-located lesions for diagnosing HCC 
were 21% and 85%, respectively. The PPV and NPV for diagnosis of HCC 
based on the lesion-growth were 90% and 93%, respectively. 
Conclusions: Because of the low PPV of non-wedge-shaped, centrally-located 
early enhancing lesions in the diagnosis of HCC, the serial follow-up for 
examining lesion growth is essential to the correct diagnosis of the small arterial 
hypervascular lesions in the cirrhotic liver. 
 
 
 
 
 
 
 
 
 
 
 
 
 
--------------------------------------------------- 
Key words : multiphase dynamic CT, cirrhotic liver, hepatocellular carcinoma, 
arterioportal shunt 
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I. Introduction 
Hepatocellular carcinoma (HCC) is the most common primary hepatic 
malignancy worldwide, and most of the lesions develop in the cirrhotic liver 
from hepatitis B or C, or chronic alcohol abuse.1 Contrast-enhanced dynamic 
CT plays an important role in the periodic screening or follow-up imaging of 
the cirrhotic liver for early detection and characterization of HCCs, and the 
majority of HCCs are hypervascular compared to the background parenchyma 
during arterial phase imaging. On portal venous or equilibrium phase images, 
HCCs usually show decreased attenuation relative to the liver parenchyma (also 
referred to as “washout” of intralesional contrast).2-5 For the small 
hypervascular HCCs, however, an iso-attenuating or iso-intense appearance 
relative to the liver parenchyma on portal venous and equilibrium phase images 
of CT or MR imaging is common and frequently presents a diagnostic dilemma. 
The differential diagnosis for small arterial hypervascular lesions in this setting 
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includes an area of perfusion abnormality such as non-tumorous arterioportal 
shunts (APSs), HCCs, localized fibroses and unusually hypervascular benign or 
borderline cirrhotic nodules.6-11 
To establish a diagnostic and therapeutic strategy for the small 
hypervascular lesions in the cirrhotic liver, we assumed that the CT features of 
these early enhancing lesions would reflect the nature and clinical behavior of 
the lesion. In the present study, we tried to determine the significance of small 
hypervascular enhancing lesions in the cirrhotic liver exclusively defined on 
arterial phase images of multiphase dynamic CT depending on their contour, 
size and location of the lesions on the initial CT in addition to the interval 
growth on the follow-up imaging studies.  
 
II. Materials and Methods 
1. Patients and CT 
This retrospective study was approved by our Committee for Clinical 
Investigations and conducted according to the institutional review board rules 
for departmental review of records for research, and informed consent from 
subjects was waived. Electronic medical records of the patients who were 
examined in at least one session of multiphase IV contrast-enhanced dynamic 
CT for the assessment of focal lesions in the cirrhotic liver over a 5-year period 
(from April 2000 to December 2004) were searched by personnel from the 
clinical information center.  
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Multiphase contrast-enhanced dynamic CT (unenhanced, arteral, portal, 
and delay phases) was performed with a helical CT scanner (HiSpeed 
Advantage; General Electric Medical Systems, Milwaukee, WI) or a 
multichannel unit (Somatom Sensation 16; Siemens, Erlangen, Germany). After 
the intravenous administration of 150 mL of iodinated contrast agent (Ultravist 
300; Schering AG, Berlin, Germany) given by an automatic injector 
(EnVisionCT; Medrad, Pittsburgh, PA) at 3 mL/s, arterial, portal and delay 
phase imaging was started after a delay of 25-30 seconds, 65-70 seconds and 
150 seconds, respectively, on the helical scanner. In the multichannel unit, a 
15-second delay from the time of 100 Hounsfield units of aortic enhancement 
was set as the starting time of arterial phase imaging using the SmartPrep 
technique12 followed by portal phase imaging conducted at 30 seconds from the 
start point of arterial phase imaging. Three-minute delayed equilibrium phase 
imaging was added for the triple-phase imaging. All scans were sent to the 
picture archiving and communication system (PACS) for interpretation on the 
PACS workstations. 
For patient selection, two radiologists including one attending radiologist 
with 12 years of experience in liver imaging and a junior resident retrieved the 
imaging data and conducted the PACS monitor preliminary review together. To 
be enrolled in the present study, a patient was required to have at least one small 
hypervascular enhancing lesion (larger than 5 mm and smaller than 30 mm) on 
arterial phase of dynamic CT examination but showed iso-attenuation that could 
 6 
not be distinguished from the background cirrhotic liver on the equilibrium 
phase images. There should be no lesional hypoattenuation suggesting 
“washout” of contrast material on the portal venous phase images. For the 
diagnosis of HCC, the lesion was verified histologically or by a combination of 
clinical and radiological criteria.13,14 These included increased tumor marker 
levels and interval tumor growth (≥ 2 mm in the longest dimension) during the 
follow-up examinations within one year. These criteria were used in addition to 
the sustaining nodular accumulation of iodized-oil (Lipiodol; Guerbet, 
Aulnay-sous-Bois, France) after transcatheter arterial chemoembolization 
(TACE) for the hypervascular lesions defined on the digital subtraction hepatic 
arteriography. For lesions larger than 1 cm, arterial hypervascularity with a 
subsequent washout appearance on follow-up CT or MR imaging combined 
with hypervascular tumor staining on hepatic arteriography was also defined as 
HCC according to the recent criteria stated by European Association for Study 
of the Liver (EASL), which were modified by a recent review.15,16 The diagnosis 
of hypervascular benign lesions or pseudolesions was determined when the 
lesion disappeared or decreased in size based on results of serial imaging 
studies within one year. Lesions stable in size on follow-up dynamic CT or MR 
imaging study at least one year afterward were considered a pseudo- or benign 
lesion.17 To rule out the possibility of a slowly growing tumor, patients with 
enhancing lesions that were stable or decreasing in size on serial CT scans and 
had less than 12 months of follow-up with dynamic CT scans were excluded. In 
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addition, hypervascular lesions corresponding to the typical small non-tumorous 
APS defined by hepatic arteriography were also regarded as a benign.6 
Thirty-four patients having 77 lesions on initial CT studies underwent hepatic 
arteriography during the follow-up period. Of these lesions, 28 HCCs with 
hypervascular tumor stainings were revealed in 20 patients and 34 typical 
non-tumorous APSs were detected in the tumor-free area during follow-up 
imaging studies in 17 patients. The remaining 15 hypervascular lesions were not 
defined on the hepatic arteriography. Consequently, the study population 
included 67 patients with 169 lesions (HCC, n = 28 in 20 patients; benign, n = 
141 in 60 patients including 13 patients having HCCs coincidentally), which 
were marked by electronic arrows on the arterial phase images of the initial CT, 
and the images were saved for subsequent data analysis. The patient group 
included 43 men and 24 women aged from 37 to 77 years (mean age, 58.8 
years).  
 
2. Image Analysis 
In the analysis of the imaging features of the early enhancing lesions, 
digitally stored image data were reviewed in conference by two different 
reviewers (with 5 and 14 years of experience in liver imaging, respectively) 
who had not participated in the initial patient selection and were blinded to the 
final diagnosis of the lesions. The contour (nodular, wedge-shaped, or 
irregular-amorphous) and the location (subcapsular or central) of the indicated 
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lesions were determined by a consensus of all the reviewers. The wedge-shaped 
lesion was defined as a subcapsular triangular lesion based on the liver capsule 
and centrally directed apex in the three-dimensional considerations. To be 
distinguished from the subcapsular lesions, the lesions completely embedded in 
the hepatic parenchyma were defined as central lesions regardless of the 
distance between the lesion and the liver surface. Two radiologists participated 
in the initial patient selection measured the longest dimension on a magnified 
view of the axial images with electronic calipers on the PACS monitor, and the 
size of the same lesion on follow-up imaging was also measured along the same 
direction for direct size comparisons of each lesion. The measurement process 
was repeated 14 days after the completion of the first measurement session by 
the same radiologists, and the mean value of two separate measurements was 
used for data description and subsequent analyses. The volume doubling time of 
the lesion was calculated as t divided by 10 (log d – log d0), where the lesion 
diameter increased from d0 to d in t days.18 Chi-square and logistic regression 
tests were used to determine the differential values of the various imaging 
features between HCCs and pseudo- or benign lesions. A P value of less than 
0.05 was considered statistically significant. 
 
III. Results 
The initial CT findings of the 169 small hypervascular enhancing lesions 
are summarized in Table 1. One-hundred-and-eleven (66%) of the total 169 
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lesions were smaller than 10 mm, and 58 (34%) were 10 mm or larger. Eighteen 
(64%) of 28 HCCs and 93 (66%) of 141 benign lesions were smaller than 
10mm in the longest dimension on the initial CT examination. The mean size of 
all lesions was 9.9 mm in the longest dimension, and no significant size 
difference (p = 0.44) was detected between the pseudo- or benign lesions (9.9 
mm) and HCCs (9.7 mm) on the initial CT. 
One-hundred-and-eleven (66%) of all 169 lesions were subcapsularly and 
58 (34%) lesions were centrally located. Eleven (10%) of the 111 subcapsular 
lesions and 17 (29%) of 58 intrahepatic lesions were HCCs. Considering the 
contour of the lesions, 83 (49%) were nodular, 43 (25%) showed irregular or 
amorphous appearance while the other 43 (25%) showed wedge-shape based on 
the liver surface. Seven (16%) of 43 lesions showing irregular-amorphous 
appearances and 21 (25%) of 83 nodular lesions and were HCCs (Fig. 1 and 2). 
All 43 wedge-shaped subcapsular lesions were benign. A significant difference 
was detected in the shape (p = 0.002) and the location (p = 0.041) between 
HCCs and benign lesions on the first dynamic CT examination. If the 
non-wedge shaped and intrahepatic hypervascular lesions were assumed to be 
HCCs, the positive and negative predictive values (PPV, NPV) for diagnosing 
HCC were 21% and 85%, respectively. 
Besides the 10 HCCs immediately diagnosed by increased serum alpha 
fetoprotein levels, arterial hypervascularity in the dynamic CT and hepatic 
arteriography, and sustaining accumulation of iodized-oil on follow-up CT 
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studies after transcatheter arterial chemoembolization, 159 lesions in 59 patients 
had multiple comparable serial follow-up CT data (range of length of last 
follow-up, 12-60 months; mean, 24 months). On the final follow-up CT 
examinations, 20 lesions were increased in size, 8 remained stable, and 131 
were decreased in size or no longer visible (Fig. 3 and 4). Eighteen (90%) of 20 
lesions with interval growth during the follow-up period were HCCs and 
displayed a washout appearance on portal and/or delay phase images of the 
enlarged lesions (> 1cm in long dimension) (Fig. 1 and 2). In 18 HCCs with 
interval growth, the mean interval time from the initial baseline CT scan and the 
follow up CT examination showing subsequent washout appearance for the first 
time was 6.2 months (range of interval time, 2-14 months). Six of 18 HCCs 
displayed both interval growth and subsequent washout at the first follow-up 
CT examination less than 3 months after the initial baseline examination. In ten 
of 18 HCCs with interval growth, the subsequent washout appearance was 
concurrently noted at the second follow-up CT examination less than 6 months 
after the initial examination. Two angiographically verified APSs showing 
centrally located irregular hypervascularity on the initial CT were also increased 
in size on the final follow-up dynamic CT scan, but did not show a washout 
appearance on portal or delay phase images (Fig. 5). The PPV and NPV for 
diagnosis of HCC on the basis of lesion growth were 90% and 93%, 
respectively, and the mean volume doubling time of HCCs that had multiple 
follow-up CT examinations was 4 months (with a range of 1-14 months). 
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Fig 1.—A 71-year-old man with a hepatocellular carcinoma that increased in 
size during a 12-month follow-up.  
A, Arterial phase contrast enhanced dynamic CT scan obtained at the initial CT 
examination shows a 0.6-cm-diameter, irregular early enhancing lesion (arrow 
head) in the dome of cirrhotic liver.  
B, Arterial phase contrast enhanced dynamic CT scan obtained 6 months later 
shows that the lesion (arrow head) has increased in size.  
C, Portal phase contrast enhanced dynamic CT scan obtained 6 months later 
shows a low-attenuation lesion (arrow head), which is indicative of 
hepatocellular carcinoma.  
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Fig 2.—A 55-year-old man with a hepatocellular carcinoma that increased in 
size during a 12-month follow-up.  
A, Arterial phase contrast enhanced dynamic CT scan obtained at the initial CT 
examination shows a 0.9-cm-diameter, nodular early enhancing lesion (arrow) 
in the subcapsular portion of cirrhotic liver.  
B, Arterial phase contrast enhanced dynamic CT scan obtained 12 months later 
shows that the lesion (arrow) has increased in size. 
C, Portal phase contrast enhanced dynamic CT scan obtained 12 months later 
shows a low-attenuation lesion (arrow), which is indicative of HCC.   
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Fig 3.—A 40-year-old man with a non-tumorous arterioportal shunt verified 
angiographically.  
A, Arterial phase contrast enhanced dynamic CT scan obtained at the initial CT 
examination shows a nodular lesion (arrow) in the subcapsular portion of the 
liver.  
B, Hepatic arteriography obtained 2 weeks later shows branching or dotlike 
vascular structures (arrow) that appeared early in the arterial phase followed by 
focal parenchymal contrast enhancement in the tumor-free area, which is 
compatible with the arterioportal shunt.  
C, A follow-up dynamic CT scan obtained 1 month later shows the lesion has 
disappeared. 
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Fig. 4.—A 70 year-old man with small early enhancing hepatic lesions that 
disappeared during a 12 month follow-up.  
A, Arterial phase contrast enhanced dynamic CT scan obtained at the initial CT 
examination shows irregular or nodular early enhancing lesions at the central 
portion of liver.  
B, Arterial phase contrast enhanced dynamic CT scan obtained 12 months later 
shows that previously detected abnormalities have disappeared, which is 
indicative of a perfusional pseudolesion. 
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E
 
Fig 5.—70-year-old man with a non-tumorous arterioportal shunt showing 
instability of size during follow-up the period.  
A, Arterial phase contrast enhanced dynamic CT scan obtained at the initial CT 
examination shows an irregular early enhancing lesion (arrow) at the central 
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portion of cirrhotic liver.  
B, Arterial phase contrast enhanced dynamic CT scan obtained 3 months later 
shows that the lesion (arrow) has decreased in size, which is indicative of a 
pseudolesion.  
C, Arterial phase contrast enhanced dynamic CT scan obtained 12 months later 
shows the lesion (arrow) has increased in size.  
D, The lesions was not distinguished from background hepatic parenchyma on 
the equilibrium phase of dynamic CT scan obtained 12 months.  
E, Based on hepatic arteriography obtained 12 months later, this lesion (arrow 
head) is diagnosed as a non-tumorous arterioportal shunt. 
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Table I Initial CT Features of 169 Early-Enhancing Lesions in 67 Patients 
Diameter (mm) Shape Location Final 
Diagnosis, 
No.of 
Cases(%) 
<10 10-30 Nodular Irregular Wedge Central Subcapsular 
HCC,  
28 (17) 
18 (64) 10 (36) 21 (75) 7(25) 0 17 (61) 11 (39) 
Benign, 
141 (83) 
93 (66) 48 (34) 62 (44) 36 (26) 43 (30) 41 (29) 100 (71) 
Total,  
169 (100) 
111 (66) 58 (34) 83 (49) 43 (25) 43 (25) 58 (34) 111 (66) 
Note.-  HCC = hepatocellular carcinoma 
Numbers in the parentheses are percentages of the each diagnosis out of all 169 
lesions 
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IV. Discussion 
The goal of screening patients with chronic liver disease is to detect 
HCCs while they are small, asymptomatic, and potentially curable.19 
HCC is one of the representative hypervascular tumors and imaging 
diagnosis is mostly dependent upon the arterial hypervascularity detected 
by dynamic imaging studies. Unfortunately, however, small areas of 
enhancement seen only on arterial phase imaging are common and rather 
nonspecifically demonstrated, especially in the patients with cirrhotic 
liver.  
Liver transplantation is feasible in patients with HCCs (stage I or II 
disease), since it can be curative.20 According to the American Liver 
Tumor Study Group Modified Tumor-Node-Metastasis staging 
classification, stage I tumors are those with one tumor nodule less than 
2.0 cm in diameter. Stage II tumors are those with either one nodule 
2-5cm in diameter or up to three nodules each less than 3cm in diameter. 
Therefore, if one mass less than 5cm in diameter or up to three masses 
each less than 3cm in diameter are present in the liver without evidence 
of extrahepatic metastases, transplantation can be performed.20 The 
problem of small HCC detection is particularly important when the 
patient is in the waiting list for liver transplantation.  
 19 
There have been several reports mainly regarding MR imaging of 
small hypervascular pseudolesions in cirrhotic liver.10,11,21  Ito, et al21 
reported that hypervascular pseudolesions tend to show prolonged 
enhancement during the arterial phases compared with hypervascular 
HCCs on multiarterial phase contrast-enhanced dynamic MR imaging. 
For CT, however, the excessive radiation exposure and the use of a large 
amount of contrast material at CT make limitation of multiple arterial 
phase imaging of the whole liver. There was only one report regarding 
small hypervascular nodules on dynamic CT.22 However, the previous 
report only dealt with nodular lesions and could make a bias for 
evaluation of all small hypervascualr lesions on CT by omitting the 
irregular or amorphous lesions as well as the wedge-shaped lesions.22 
For the mechanism of arterial hypervascularity, locally activated 
transvasal or transplexal communications between the small hepatic 
arteries and portal veins have been suggested to make hypervascular 
enhancing pseudolesions. This activation depends on the intrinsic 
changes related to cirrhosis itself or traumatic arterioportal fistula from 
extrinsic factors in addition to congenital variations.23-25 Early-enhancing 
lesions on arterial phase images showing a wedge-shaped appearance in 
the subcapsular portion commonly suggested non-tumorous APS in prior 
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reports.6,7,9 Besides the typical APSs of wedge-shaped subcapsular 
lesions, 28 (22.2%) of 126 non-wedge-shaped foci were diagnosed as 
HCCs and 11 (9.9%) of 111 subcapsular early-enhancing lesions seen on 
CT scans were confirmed to be HCCs in the present study. However, 
many of the subcapsular arterial hypervascular lesions were smaller than 
10 mm on the initial CT, which indicated that it would be rather difficult 
to recognize the wedge-shaped appearance even after carefully observing 
several contiguous CT images24 Moreover, regardless of the location of 
the lesions, somewhat nodular or irregular lesions can develop due to the 
parenchymal distortion in the advanced cirrhotic liver.7 
Several authors9,26,27 have suggested that most subcapsular 
enhancing lesions in cirrhotic livers were pseudolesions rather than true 
HCCs. On the basis of our study results, however, we realized that 
besides the typical wedge-shaped subcapsular pseudolesions, the contour 
or the location of early-enhancing lesions on CT scans could not reliably 
differentiate HCCs from other pseudo- or benign lesions, or vice versa, in 
the cirrhotic liver. Other studies10, 11 dealing with the small (< 20 mm) 
early-enhancing nodules on contrast-enhanced MR imaging have 
previously reported that the majority of these lesions were pseudolesions 
rather than hypervascular HCCs. Because of the difficulties in 
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confidently diagnosing small HCCs based on imaging studies, the 
follow-up of small arterial phase-enhancing lesions has been 
recommended to assess tumor growth. Follow-up MR imaging data from 
these studies10, 11 of small HCCs were similar to the data in the present 
study using CT, which is more generally used in patients undergoing 
surveillance for cirrhosis. On the follow-up CT, most of the HCCs 
showed a washout appearance of relative hypoattenuation on the portal or 
delayed phase images. 
Due to the small number of hypervascular pseudolesions that finally 
enlarged in size, the growth of the lesion was helpful in distinguishing 
the small HCCs from the pseudolesions in the present study (PPV, 90%; 
NPV, 93%). Regarding the nature of the reciprocal communications 
between the artery and portal vein in APSs, however, the extent of the 
arterial enhancement of the hepatic parenchyma is variable depending on 
the arterial perfusion pressure at the timing of image acquisition.7 This 
hemodynamic instability could cause the size variations of the 
APS-induced hypervascular foci observed on the serial follow-up 
dynamic imaging studies. From this viewpoint, the simple enlargement of 
hypervascular lesions on follow-up imaging cannot be enough to 
characterize HCC in the cirrhotic liver. 
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For the lesions that showed no hypervascular staining or shunt 
vessels on hepatic arteriography or those that immediately disappeared 
on the follow-up CT, there would still be a possibility of arterial 
hypervascularity on the initial CT studies. Somewhat localized small 
hepatic venous or portal venous thrombosis could have developed due to 
the sluggish flow from portal hypertension. The temporarily occluded 
hepatic vein could increase the sinusoidal pressure and reverse the 
pressure gradient between the sinusoidal and portal veins resulting in a 
kind of transsinusoidal APS. In such cases, the portal vein branches 
cannot be well demonstrated during the early phase of hepatic 
arteriography. In the thrombotic cases of small portal venules, the 
compensatory increase of arterial flow can also be visible as a 
hypervascular lesion on the dynamic CT, but not delineated as a direct 
APS on the hepatic arteriography. The small temporary benign venous 
thromboses might be easily resolved and tend to be noted inconstantly on 
the follow-up CT. Another possible explanation is the theory of small 
subclinical inflammation suggested by Kamura, et al28, in which small 
portal or hepatic venules could be obliterated temporarily due to 
inflammatory cell infiltrations around the pyogenic abscess29 or along the 
portal tract.30 The inflammation-induced increase in arterial 
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hypervascularity would be the only finding indicative of the 
inflammatory lesions which would then easily disappear after the 
inflammation was resolved.30, 31 
This study had several limitations. Due to the retrospective nature of 
this study, pathologic proofs of HCC were not available and angiographic 
evidence of pseudo- or benign lesions were insufficient in many of the 
cases. In the evaluation of small hypervascular lesions exclusively seen 
on arterial phase images, we routinely recommend follow-up CT or MR 
imaging rather than an immediate additional confirmative study. After 
verification of the growth of the lesions and the washout appearance on 
portal or equilibrium phase images, hepatic arteriography is generally 
performed for additional imaging information and TACE. A percutaneous 
biopsy is reserved for the gradually enlarged and hypovascular lesions in 
the cirrhotic liver. Although the majority of pseudo- or benign lesions 
would create a non-tumorous condition verified by means of follow-up 
imaging, the possibility of an extremely slow-growing small 
hypervascular tumor still exists. However, most of the non-HCC lesions 
were decreased in size or even disappeared, and only a limited number of 
stable lesions were detected during the follow-up imaging studies. We 
believe that the limited possibility of the extremely slowly growing 
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hypervascular HCC could not change our results. 
 
V. Conclusion 
In conclusion, although the majority of hypervascular lesions 
exclusively defined on the arterial phase imaging of dynamic CT were 
pseudo- or benign lesions, due to the limited value of the PPV of 
centrally located hypervascular lesions in the diagnosis of HCC, we 
could not reliably differentiate HCCs from benign conditions by means 
of the initial CT findings of the shape or locations except for the typical 
wedge-shaped subcapsular pseudolesions. Interval lesion-growth is 
highly predictive of HCC, however, due to the instability of the 
APS-induced pseudolesions, a temporary enlargement in the size of a 
hypervascular lesion itself would have a limited value to confirm the 
diagnosis of HCC. We suggest that lesion growth should be monitored in 
conjunction with the washout appearance on portal or equilibrium phase 
images on the follow-up CT studies to confirm the imaging diagnosis of 
HCC. In the present study, the mean volume doubling time of small 
hypervascular HCCs that initially showed no washout appearance on 
portal or delayed phase imaging was 4 months, which would be a suitable 
interval to arrive at the correct diagnosis and management of 
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subcentimeter HCCs. When small hepatic arterial phase-enhancing 
lesions on dynamic CT scan are observed, a serial, close follow-up of the 
lesions is still essential for correct diagnosis. 
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간경변증 환자의 다중위상 전산화 단층 촬영시 동맥기에서 
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황 성 호  
 
 
목적: 간경변증 환자를 대상으로 시행한 역동적 전산화 단층 촬영시
동맥기에서만 과혈관성을 보이는 작은 병변들의 악성빈도와 관련된 
영상소견의 의의를 알아보았다. 
방법: 총 67명의 간경변증 환자에서 시행한 역동적 전산화 단층 촬영
에서 동맥기 과혈관성을 보이는 작은 병변들 (직경 > 5mm 그리고 < 
30mm) 중 문맥기와 평형기에 주변 간조직과의 감쇄밀도차이를 보이
지 않는 169개를 연구대상으로 하였다. 이들 병변들을 최종 진단에 
따라 구분하고 각각의 위치, 경계, 그리고 크기변화를 후향적으로 비
교분석 하였다.  
결과: 총 169개의 병변들 중 28개(17%)가 간세포암이었고 나머지는 
양성 혹은 거짓 병변들 이었다. 간실질 중심부에 위치한 병변들 
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(n=58) 중 악성은 17개(29%)였고 소결절성 또는 불규칙한 모양의 병
변들 (n=126) 에서 악성은 28개(22%)였다. 피막하에 위치한 쐐기모양
의 병변들 (n=43)은 모두 양성이었다. 이런 간세포암과 양성 병변들 
사이에는 병변의 모양 (p=0.002) 및 위치 (p=0.041)에서 유의한 차이가 
있었다. 하지만 간실질 중심부에 위치한 비쐐기모양의 병변을 간세포
암으로 간주하였을 때 양성 예측도는 21%, 음성 예측도는 85%에 그
쳤다. 병변의 크기 증가 여부를 기준으로 간세포암을 진단하였을 때 
양성 예측도는 90%, 음성 예측도는 98%였다.  
결론: 간경변증 환자의 역동적 전산화 단층촬영시 동맥기에 과혈관성
을 보이는 작은 병변들 중 간실질 중심부에 위치한 결절성 또는 불규
칙한 모양을 보이는 병변들을 악성으로 가정시 악성 예측도는 높지 
않다. 추후 연속적인 추적 검사를 통한 병변의 크기증가 확인이 보다 
정확한 진단을 위해 중요하다.  
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